Cargando…
Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey
PURPOSE: We conducted a retrospective study to evaluate the efficacy and related costs of using two different molecules of granulocyte-colony stimulating factor (G-CSF) (lenograstim – LENO or filgrastim – FIL) as primary prophylaxis of chemotherapy-induced neutropenia in a hematological inpatient se...
Autores principales: | Innocenti, Rolando, Rigacci, Luigi, Restelli, Umberto, Scappini, Barbara, Gianfaldoni, Giacomo, Fanci, Rosa, Mannelli, Francesco, Scolari, Francesca, Croce, Davide, Bonizzoni, Erminio, Perrone, Tania, Bosi, Alberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312059/ https://www.ncbi.nlm.nih.gov/pubmed/30643475 http://dx.doi.org/10.2147/JBM.S186786 |
Ejemplares similares
-
Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey [Corrigendum]
Publicado: (2019) -
Monocentric Analysis of the Effectiveness and Financial Consequences of the Use of Lenograstim versus Filgrastim for Mobilization of Peripheral Blood Progenitor Cells in Patients with Lymphoma and Myeloma Receiving Chemotherapy and Autologous Stem Cell Transplantation
por: Restelli, Umberto, et al.
Publicado: (2020) -
Home administration of filgrastim (Nivestim™) in primary prophylaxis of chemotherapy-induced febrile neutropenia
por: Otremba, Burkhard, et al.
Publicado: (2018) -
Primary prophylaxis with biosimilar filgrastim cost-effective approach to avoid febrile neutropenia
Publicado: (2021) -
Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy
por: Restelli, Umberto, et al.
Publicado: (2017)